openPR Logo
Press release

A cost effective way of treating the homeless schizophrenic population in Edmonton & Alberta

03-28-2006 05:55 PM CET | Health & Medicine

Press release from: Golden Meteorite Press

There are approximately 600 homeless schizophrenics in Edmonton, 1,900 homeless schizophrenics in Alberta & 19,000 homeless schizophrenics in Canada!(06% of the population are homeless schizophrenics. Source: www.schizophrenia.com )
My perspective is that at least for the schizophrenic segment of this population the cost would be a modest amount using the technology of Risperdal Consta.
Government and the public keep talking about solving the homeless problem. Ironically Risperdal Consta could solve the problem of schizophrenic homelessness without the bureaucracy or medical personnel. Without Risperdal Consta the government could spend many millions dollars treating homeless schizophrenics making any impact whatsoever.
Austin Mardon, Ph.D. a schizophrenic for 13 years has been on a medical study where he is receiving an atypical neuroleptic in an experiment for over three months says, “I have noticed a world of difference. It is like I am a new man! How many 1,900 homeless schizophrenics in Alberta could be saved from the nightmare of psychosis by getting this new drug?”

-30-



Contact:
Austin Albert Mardon, Ph.D.
Telephone 780-378-0063
Email:amardon@shaw.ca

Backrounder

A cost effective way of treating the homeless schizophrenic population in Edmonton & Alberta.
There are approximately 600 homeless schizophrenics in Edmonton, 1,900 homeless schizophrenics in Alberta & 19,000 homeless schizophrenics in Canada!(06% of the population are homeless schizophrenics. Source: www.schizophrenia.com )
My perspective is that at least for the schizophrenic segment of this population the cost would be a modest amount using the technology of Risperdal Consta. If the average dose of Risperdal Consta is approximately $500 per homeless schizophrenic per month, then that means it would cost $6,000 per year per person for that medication giving an injection of the medication every two weeks .To treat the 600 people in Edmonton with Risperdal Consta would cost $3 million total per year.
I am extremely disturbed that Risperdal Consta is not on the formulary because it has the potential with the new technology of injectable atypical neuroleptics. It is impossible to guarantee or know whether a homeless or non-compliant schizophrenic has taken a pill every day. You would need to have an army of nurses following people around everyday giving them their medicine, and even then they could “cheek” their medicine. That is they could keep the medication in their cheek and then when no one is looking they could spit out the medication. But with Risperdal Consta, you would only need a nurse to give an injection once every two weeks, and a general practitioner to initially diagnose the homeless schizophrenic.
It is much easier to manage an injection once every two weeks logistically and financially than to give a pill every day. Government and the public keep talking about solving the homeless problem. Ironically Risperdal Consta could solve the problem of schizophrenic homelessness without the bureaucracy or medical personnel. Without Risperdal Consta the government could spend many millions dollars treating homeless schizophrenics making any impact whatsoever.
The solution is not more personnel or doctors but to get every homeless schizophrenic an injection of Risperdal Consta every two weeks. I know that not every person who is homeless with schizophrenia would respond positively to the treatment and recover, but if 50% recovered, that would mean that over 300 schizophrenic persons that are homeless in Edmonton and will live on the street and will be in a psychotic haze may be able to get sane enough to have a life.
The homeless schizophrenics are not homeless because they choose to be, but because they are incapable of functioning in society while unmedicated. When over ten Alberta families and recovered homeless schizophrenics were asked to comment for this press release they felt they could not because of the stigma, guilt that they feel because they have schizophrenia.
It is just another disease but people are ashamed to be public about the illness due to negative societal repercussions.
Austin Mardon, Ph.D. a schizophrenic for 13 years has been on a medical study where he is receiving an atypical neuroleptic in an experiment for over three months says, “I have noticed a world of difference. It is like I am a new man! How many 1,900 homeless schizophrenics in Alberta could be saved from the nightmare of psychosis by getting this new drug?”
-30-
Contact:
Austin Albert Mardon, Ph.D.
Golden Meteorite Press
Involved with the publication of scholarly material in Alberta.
Telephone 780-378-0063
Email:amardon@shaw.ca

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release A cost effective way of treating the homeless schizophrenic population in Edmonton & Alberta here

News-ID: 6979 • Views:

More Releases from Golden Meteorite Press

Schizophrenics get grace from Pope
The following is a letter that was presented to Archbishop Thomas Collins that was forwarded to Pope Benedict XVI related to the recent indulgence announced for the mentally ill as it relates to schizophrenia. "We wish to express our thanks that the Catholic Church now has an indulgnace for the service of the mentally ill through the foresight of Pope Benedict XVI. Their are over 10 million people who have

More Releases for Risperdal

Risperdal Market Massive Growth opportunity Ahead
The global Risperdal market is valued at approximately $1.8 billion in 2024 and is projected to reach around $2.5 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period from 2025 to 2034. Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Risperdal market goods. The market study excludes key regions that
Top Companies in the Risperdal Market Set for Success by 2032 | Hetero Healthcar …
The Risperdal Market research report provides important information about the industry's evolution, emphasizing the primary growth drivers and revenue streams anticipated between 2024 and 2032. It aids companies in navigating the intricacies of the market by highlighting both the current state of affairs and the most recent advancements impacting its course, much like a compass. This report is a strategic ally for businesses, stakeholders, and industry participants because it provides
EGFR Antibody Market Key Growth Drivers, Competitive Landscape and Global Foreca …
The EGFR Antibody Market is experiencing significant growth driven by rising cancer prevalence and advancements in targeted therapies. Epidermal Growth Factor Receptor (EGFR) antibodies are crucial in treating various cancers, including lung and colorectal cancers, by inhibiting cell proliferation. The market is expanding due to increased R&D activities, new product approvals, and growing awareness of personalized medicine. North America dominates the market due to its strong healthcare infrastructure, while Asia-Pacific
Bipolar Disorder Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Bipolar Disorder Pipeline Insight 2024" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Bipolar Disorder pipeline landscape. It covers the Bipolar Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Bipolar Disorder Pipeline
Risperdal Market 2023 Driving Factors Forecast Research 2029
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Risperdal market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role in determining the
Waters & Kraus Congratulates TAF Whistleblower of the Year Allen Jones
Taxpayers Against Fraud Education Fund Honors Waters & Kraus Client for Fighting Medicaid Fraud by Drug Company WASHINGTON, DC — September 17, 2012 — Last Thursday night, the non-profit public interest organization Taxpayers Against Fraud Education Fund (TAF) honored Waters & Kraus client Allen Jones for blowing the whistle on alleged fraud and illegal kickbacks by Johnson & Johnson subsidiary, Janssen Pharmaceutical, Inc. Mr. Jones, a former Pennsylvania healthcare fraud investigator